Abnormal structure-function relationships in hereditary dystonia

Area of Science:

• Neuroscience
• Genetics
• Movement Disorders

Background:

• Primary torsion dystonia (PTD) is a chronic movement disorder characterized by sustained muscle contractions and abnormal postures.
• Inherited forms of PTD are linked to specific gene mutations (DYT1, DYT6) with incomplete clinical penetrance (around 30%).
• PTD is increasingly viewed as a neurodevelopmental disorder affecting cortico-striatal-pallido-thalamocortical (CSPTC) pathways.

Purpose of the Study:

• To investigate functional and microstructural brain abnormalities in manifesting and non-manifesting carriers of PTD-associated mutations.
• To explore the relationship between genotype, phenotype, clinical penetrance, and brain imaging findings.
• To understand the neurobiological underpinnings of PTD and identify potential therapeutic targets.

Main Methods:

• Positron emission tomography (PET) to assess regional brain metabolism.
• Diffusion tensor magnetic resonance imaging (DTI) to evaluate white matter microstructure and connectivity.
• Analysis of resting regional metabolism and motor activation responses in mutation carriers.

Main Results:

• Consistent metabolic abnormalities were observed in PTD, involving interconnected elements of CSPTC and related pathways.
• Genotype-specific metabolic changes in the striatum correlated with D(2) receptor availability.
• A unique penetrance-related metabolic network was identified, with increased activity in pre-supplementary motor area (SMA) and parietal regions, and decreased activity in the cerebellum, brainstem, and ventral thalamus.
• DTI data suggest metabolic abnormalities may reflect adaptive responses to altered motor pathway connectivity.
• Increased motor activation responses in carriers are consistent with reduced cortical inhibition.

Conclusions:

• PTD is a neurodevelopmental circuit disorder with distinct metabolic and microstructural brain alterations.
• These abnormalities are linked to genotype, phenotype, and clinical penetrance, particularly involving CSPTC pathways.
• Future research should focus on the relationship between these findings and clinical penetrance, and explore treatment reversibility.